Mira Dx Dismisses Study Questioning Clinical Value of Ovarian Cancer Risk Test

A recent study from the Ovarian Cancer Association Consortium found that the genetic marker used in the test is not predictive of ovarian cancer risk, but a MiraDx official criticized the study's methodology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.